Pe
Non verificato

Personalis, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute
26/02/2026
Mercato azionario
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
1.00
17/02/2026
Oncologia
Salute
Biotecnologia
Sanità
Eventi
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
1.00
12/02/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
1.00
10/02/2026
Salute
Biotecnologia
Oncologia
Industria
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
1.00
02/02/2026
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Scienza
Oncologia
Industria
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
1.00
12/01/2026
Biotecnologia
Salute
Farmaceutica
Oncologia
Industria
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
1.00
08/01/2026
Mercato azionario
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
1.00
11/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0